FDA approves Zoll Respicardia’s next-gen Remedē system

The Remedē  EL-X implantable neurostimulation system [Image courtesy of Zoll Respicardia]Zoll Medical, an Asahi Kasei company, announced today that the FDA has approved its next-gen Remedē  EL-X implantable neurostimulation system to treat severe sleep apnea.

Zoll acquired the technology through its acquisition of Respicardia in April.

Improvements to the new Remedē  EL-X include:

40% longer average battery life versus the previous version; Three-fourths the size of the previous version; A single lead, single-port system providing both stimulation and sensing from a single lead; Data-driven clinical insights with Drēam View, which includes full-night, comprehensive diagnostic capabilities.

“The next-generation Remedē system is built on the proven success of the current platform, with the needs of both patients and clinicians in mind,” Pete Sommerness, president of Zoll Respicardia, said in a news release. “The increased longevity, smaller size, enhanced d…

Read more
  • 0

DTW Podcast: How is Zimmer Biomet waging the ortho data war? Do medical devices carry physics-based biases?

This week’s DeviceTalks Weekly Podcast guests

In this week’s DeviceTalks Weekly Podcast,  Liane Teplitsky, vice president and general manager of worldwide robotics at Zimmer Biomet, shares her excitement for the burgeoning data business emerging in orthopedics.

Teplitsky, an engineer who built her medtech career in cardiac R&D and sales at St. Jude and Abbott, walks us through the interconnected offerings of Zimmer’s ZB edge suite of digital and robotics technologies.

In a separate interview, we talk with Achuta Kadambi, assistant professor at the UCLA Samueli School of Engineering, about a column he contributed to Science suggesting physics may be causing medical devices to perform at varying levels in people of different races.

Kadambi explains his own work in the field and suggests how medical device developers may want to move forward in the future.

See our initial report in Medical Design and Outsourcing here.

Chris New…

Read more
  • 0

Zoll Medical acquires Respicardia

Zoll Medical said today that it has acquired Respicardia and its neurostimulation tech for treating sleep apnea.

The financial terms of the deal were not disclosed.

Respicardia makes implantable neurostimulators to treat moderate to severe central sleep apnea (CSA). The system is FDA approved to treat severe CSA in adult patients with reduced cardiac function.

“Zoll and Respicardia both develop innovative therapies for conditions with large unmet clinical needs, and we share a deep commitment to improving patient outcomes,” Zoll Medical CEO Jon Rennert said in a news release. “With this acquisition, Zoll will combine its expertise in cardiac and respiratory care with Respicardia’s novel Remedē System to make a meaningful difference in the health and quality of life for many patients.”

A cardiac electrophysiologist implants Respicardia’s system during a minimally invasive outpatient procedure. It delivers electrical pulses to one of the phren…

Read more
  • 0